|
|
|
|
|
WHAT TO EXPECT FROM THE UPCOMING ASCO 2023 ANNUAL MEETING
|
|
|
|
|
|
| Poster Session: Genitourinary Cancer--Kidney and Bladder - 08:00 - 11:00 CST |
|
|
|
|
CD8 Cell PET Imaging with 89-zr-crefmirlimab Berdoxam (Crefmirlimab) in Patients with Metastatic Renal Cell Carcinoma Receiving Checkpoint Inhibitors: Association with Response and Tissue CD8 Expression
Presented By: Sumanta Kumar Pal, MD, FASCO
|
|
|
|
|
|
Belzutifan Plus Lenvatinib for Patients With Advanced Clear Cell Renal Cell Carcinoma After Progression on a PD-1/l1 and VEGF Inhibitor: Preliminary Results of Arm B5 of the Phase 1/2 KEYMAKER-U03B Study
Presented By: Laurence Albiges, MD, PhD
|
|
|
|
|
|
Assessment of Short-chain Fatty Acid and Circulating Cytokine Trends in a Clinical Trial of Nivolumab/Ipilimumab and CBM588 in Metastatic Renal Cell Carcinoma
Presented By: Nazli Dizman MD
|
|
|
|
|
|
Patient Priorities and Expectations of Systemic Therapy in Metastatic Renal Cell Carcinoma
Presented By: Dena Battle, BS
|
|
|
|
|
|
Phase I/II Randomized Clinical Trial of In-Clinic Acupuncture Prior to BCG in Patients With High-Risk Non-Muscle Invasive Bladder Cancer
Presented By: Sarah Psutka, MD, MS
|
|
|
|
|
|
Biology and Performance of Pre- and Post-Pembrolizumab Vesical Imaging–reporting and Data System (VI-RADS) to Predict the Pathological Response in Muscle-Invasive Urothelial Bladder Cancer: Full Data Analysis From a Clinical Trials Pipeline
Presented By: Andrea Necchi, MD
|
|
|
|
|
|
A First-in-Human Trial of Intravesical Enfortumab Vedotin, an Antibody-Drug Conjugate, in Patients With Non-Muscle Invasive Bladder Cancer: Interim Results of a Phase 1 Study (EV-104)
Presented By: Andrea Necchi, MD
|
|
|
|
|
|
|
|
| Poster Session: Genitourinary Cancer--Prostate, Testicular, Penile - 08:00 - 11:00AM CST
|
|
|
|
|
Prostate Irradiation in Men With De Novo, Low-Volume, Metastatic, Castration-sensitive Prostate Cancer: Results of PEACE-1, a Phase 3 Randomized Trial With a 2x2 Design
Presented By: Alberto Bossi, MD
Development and Validation of an AI-derived Digital Pathology-based Biomarker to Predict Benefit of Long-Term Androgen Deprivation Therapy With Radiotherapy in Men With Localized High-Risk Prostate Cancer Across Multiple Phase III NRG/RTOG Trials
Presented By: Andrew J. Armstrong, MD
Association of Plant-Based Diet Index With Quality of Life in Patients With Prostate Cancer
Presented By: Stacy Loeb MD, PhD, MS.
|
|
|
|
|
|
|
|
|
|
Assessing PSA Levels as Prognostic of Overall Survival in Men With Metastatic Hormone-sensitive Prostate Cancer
Presented By: Susan Halabi, PhD, FASCO
|
|
|
|
|
|
The Relationship Between a Priori Defined Prognostic Risk Groups and and Overall Survival in Men With Metastatic Hormone Sensitive Prostate Cancer
Presented By: Susan Halabi, PhD, FASCO
|
|
|
|
|
|
PSMA PET Findings in an “EMBARK-like” Cohort of Patients With High-Risk Non-Metastatic Hormone-Sensitive Prostate Cancer: a Single Center Post-Hoc Retrospective Analysis
Presented By: Wesley Armstrong, BS
|
|
|
|
|
|
Final Results From Phase I Study of PSCA-targeted Chimeric Antigen Receptor (CAR) T Cells in Patients With Metastatic Castration Resistant Prostate Cancer
Presented By: Tanya B. Dorff, MD
|
|
|
|
|
|
Tumour Factors and the Variation in Non-Muscle Invasive Bladder Cancer Recurrence After Transurethral Resection Surgery Between Sites: Results From the RESECT Study
Presented By: Fortis Gaba
|
|
|
|
|
|
First-line Lenvatinib + Pembrolizumab Treatment Across Non-Clear Cell Renal Cell Carcinomas: Results of the Phase 2 KEYNOTE-b61 Study
Presented By: Chung-Han Lee, MD, Ph.D.
|
|
|
|
|
|
| Oral Abstract Session: Genitourinary Cancer--Prostate, Testicular, and Penile - 08:00 - 11:00AM CST
|
|
|
|
|
Prostate Irradiation in Men With De Novo, Low-Volume, Metastatic, Castration-sensitive Prostate Cance: Results of PEACE-1, a Phase 3 Randomized Trial With a 2x2 Design
Presented By: Ken Herrmann, MD
Digital Histopathology-Based Multimodal Artificial Intelligence Scores Predict Risk of Progression in a Randomized Phase III Trial in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
Presented By: Felix Y Feng, MD
Prognostic Impact of PSA Nadir ≥0.1 Ng/ml Within 6 Months After Completion of Radiotherapy for Localized Prostate Cancer: an Individual Patient-data Analysis of Randomized Trials From the ICECAP Collaborative
Presented By: Praful Ravi, MRCP, MBBChir
|
|
|
|
|
|
|
|
|
|
Presence of Somatic/Germline Homologous Recombination Repair Mutations and Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Receiving First‑line Treatment Stratified by BRCA Status
Presented By: David Olmos, MD, PhD
|
|
|
|
|
|
TALAPRO-2: Phase 3 Study of Talazoparib + Enzalutamide Versus Placebo + Enza as First-line Treatment for Patients With Metastatic Castration-resistant Prostate Cancer Harboring Homologous Recombination Repair Gene Alterations
Presented By: Karim Fizazi, MD
|
|
|
|
|
|
LuPARP: Phase 1 Trial of 177lu-PSMA-617 and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer
Presented By: Shahneen Sandhu, MBBS, FRACP
|
|
|
|
|
|
Long Term Follow-up Analysis of Plasma miR371 Expression to Detect Early Relapse in Patients With Clinical Stage I Testicular Germ Cell Tumors on Surveillance
Presented By: Lucia Nappi, MD, PhD, FRCPC
|
|
|
|
|
|
The Genomic and Transcriptomic Landscapes of Chemotherapy Naïve Vs Post-chemotherapy Germ Cell Tumors
Presented By: Aditya Bagrodia, MD
|
|
|
|
|
|
Primary Retroperitoneal Lymph Node Dissection in Seminoma Stage IIA-IIC ≤3cm: Combined Results of the Swenoteca (Swedish Norwegian Testicular Cancer Group) and Cologne
Presented By: Torgrim Tandstad, MD, PhD
|
|
|
|
|
|
|
|
| Oral Abstract Session: Late-Breaking Abstract Session: Presentation and Discussion of LBA4619 - 07:30 - 8:00AM CST
|
|
|
|
|
Phase 3 THOR Study: Results of Erdafitinib Versus Chemotherapy in Patients With Advanced or Metastatic Urothelial Cancer With Select Fibroblast Growth Factor Receptor Alterations
Presented By: Yohann Loriot, MD, PhD
|
|
|
|
|
|
| Oral Abstract Session: Genitourinary Cancer--Kidney and Bladder - 11:30-14:30 PM CST |
|
|
|
|
Efficacy and Safety of Atezolizumab Plus Cabozantinib Vs Cabozantinib Alone After Progression With Prior Immune Checkpoint Inhibitor Treatment in Metastatic Renal Cell Carcinoma: Primary PFS Analysis From the Phase 3, Randomized, Open-label CONTACT-03 Study
Presented By: Toni K. Choueiri, MD
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Therapy for Advanced Clear Cell Renal Cell Carcinoma: 5-year Analysis of KEYNOTE-426
Presented By: Brian I. Rini, MD, FASCO
Final Prespecified Overall Survival Analysis of CLEAR: 4-year Follow-up of Lenvatinib Plus Pembrolizumab (L+p) Vs Sunitinib in Patients With Advanced Renal Cell Carcinoma
Presented By: Thomas E. Hutson, DO, FACP, PharmD
|
|
|
|
|
|
|
|
|
|
Overall Survival by Response to First-line Induction Treatment With Atezolizumab + Platinum/gemcitabine Vs Placebo + Plt/gem in Patients With Metastatic Urothelial Carcinoma: Updated Data From the IMvigor130 OS Final Analysis
Presented By: Enrique Grande, MD
|
|
|
|
|
|
Erdafitinib Vs ERDA Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and Fibroblast Growth Factor Receptor Alterations: Final Results From the Phase 2 NORSE Study
Presented By: Arlene O. Siefker-Radtke, MD
|
|
|
|
|
|
Study EV-103 Dose Escalation/cohort A: Long-term Outcome of Enfortumab Vedotin + Pembrolizumab in First-line Cisplatin-ineligible Locally Advanced or Metastatic Urothelial Carcinoma (La/muUC With Nearly 4 Years of Follow-up
Presented By: Shilpa Gupta, MD
|
|
|
|
|
|
Adjuvant Nivolumab Plus Ipilimumab Vs Placebo for Patients With Localized Renal Cell Carcinoma at High Risk of Relapse After Nephrectomy: Subgroup Analyses From the Phase 3 Checkmate 914 (Part a) Trial
Presented By: Robert J. Motzer, MD
|
|
|
|
|
|
Multicenter Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: Overall Survival Data at 5 Years in the GETUG/AFU V05 Vesper Trial
Presented By: Christian Pfister, MD, Ph.D.
|
|
|
|
|
|
SWOG S1011: a Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer
Presented By: Seth Lerner, MD
|
|
|
|
|
|
|
|
| Doublet and Triplet Therapy for mRCC: The More the Merrier or Is Three a Crowd? - 11:30-14:30 PM CST
|
|
|
|
|
The Case for Doublet Therapy
Presented By: Laurence Albiges, MD, Ph.D.
|
|
|
|
|
|
The Case for Triplet Therapy
Presented By: Katy Beckermann, MD, Ph.D.
|
|
|
|
|
|
Factors That Influence Decision-Making
Presented By: Naomi Haas, MD
|
|
|
|
|
|
|
